Ecnoglutide
Ecnoglutide (XW003) is a GLP-1 agonist being developed for the treatment of obesity and type 2 diabetes Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent .... In preclinical trials, "Ecnoglutide showed a favorable potency, pharmacokinetic, and tolerability profile, as well as a simplified manufacturing process" compared to other GLP-1 agonists. A phase 3 trial published in 2025 showed double-digit weightloss over a 48 week treatment. References GLP-1 receptor agonists Experimental diabetes drugs {{Med-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]